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had been exposed to nitrofurantoin during the first trimester of 
pregnancy. Exposure to nitrofurantoin was not associated with an 
increased risk of birth defects in general (adjusted OR, 0.850 [95% 
CI, 0.669–1.080]) or specific malformations.
Conclusion: First-trimester exposure to nitrofurantoin was not asso-
ciated with increased risk for major birth defects as well as other 
specific malformations.
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Introduction: Understanding the gap between evidence-based medi-
cine and clinical practice is necessary to improve clinical outcomes in 
children. This study aimed to investigate the most used drugs, ana-
lyzed in defined daily doses (DDD), in the Danish paediatric wards 
within 1 year.
Patients (or Materials) and Methods: Data were extracted from a 
Danish database, which contains information about the number of 
DDD sold to the hospital pharmacies including what is sold to the 
pediatric wards, hereby estimating the pediatric drug use. Two analy-
ses were made regarding the drug consumption. A main analysis cov-
ering the 90% most used drugs where the extent of off-label use and 
the number of drugs having a Pediatric Investigation Plan (PIP) were 
explored. Nationwide, 16 hospitals were included representing both 
general and specialized pediatric departments. Secondly, a test sample 
analysis was made regarding drug use during hospital admission, 
covering 80% of the pediatric standard medicine assortments from 
3 hospitals; results from the remaining hospitals are being prepared.
Results: One hundred drugs constituted the 90% most used drugs 
in the pediatric wards. Divided by anatomical classification (ATC), 
treatment of infections (J), drugs used for alimentary tract and metab-
olism problems (A), and antineoplastic and immunomodulating 
agents (L) were most prescribed. The subgroup L has not been among 
the most used ATC groups before, the expenses for this subgroup 
constitutes 25% of the entire pediatric medicine budget. Fifteen drugs 
(15%) were by all indications off label, the amount of DDD used off 
label accounted for 9.2%. A PIP existed on 25 drugs in total. The 
average time from central authorization to completed PIP was 8.5 
years, and 32% of the PIPs were completed by 2013. Preterm and 
newborns were included in 25% of the PIPs and adolescents in 64%. 
In the test sample 71% of the drugs were repeated when compared 
with the results from the main analysis. The immunomodulating 
agents were not included. Contrary to the main analysis, drugs aimed 
at the nervous system (N) were among the most used subgroups.
Conclusion: The PIP is a fairly new step toward evidence-based 
medicine ensuring the safety, efficacy, and positive risk-benefit bal-
ance by assessing clinical trials in children. However, only one fourth 
of 100 most used drugs in pediatric wards have a PIP and only 8 of 
these are completed. As a consequence, off-label drug use is frequent 
in Danish children and rational guidance regarding prescriptions in 
several areas is needed.
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Introduction: Daptomycin is a lipopeptide antibiotic with rapid con-
centration-dependent bactericidal action against Gram-positive organ-
isms. Target daptomycin plasma concentrations have been determined 
in animal models for some pathogens, but data on optimal exposure in 
humans are still lacking. Measurement of daptomycin plasma concentra-
tion is available at our institution since 2009 and is performed regularly. 
The aim was to assess variability of daptomycin plasma concentrations 
and the main determinants influencing daptomycin exposure.
Patients (or Materials) and Methods: We retrospectively collected 
data in patients with at least 1 determination of daptomycin plasma 
concentrations during the period of January 2009 to February 2012 
at the University Hospital of Zurich. Samples were analyzed by 
LC-MS/MS. Because daptomycin is mainly eliminated by the kid-
neys, exposure in patients with no renal replacement therapy (nRT), 
intermittent RT (iRT), and continuous RT (cRT) was compared. A 
trough level (Cmin) of at least 10 mg/L and a minimal peak level (Cmax) 
of 50 mg/L were defined as optimal based on animal data.
Results: Ninety patients were identified with a mean (SD) age of 
59 (16) years and a mean body weight of 74 (21) kg with 15 (16%) 
patients having a BMI > 30. The mean total daptomycin dose was 448 
(133) mg (range, 175–1000 mg). In 22%, daptomycin was adminis-
tered every 48 hours and in 1% every 36 hours. Mean Cmax was 66.2 
mg/L (n = 247; range, 20–236 mg/L) and mean Cmin was 16.7 mg/L 
(n = 116; range, 2–68 mg/L). Cmax and Cmin levels were significantly 
lower in cRT (52 [20] mg/L and 9.5 [7] mg/L, respectively) compared 
with nRT (75.6 [42] mg/L and 21.4 [16] mg/L, P < 0.0001). Cmin 
below 10 mg/L was found in 69% of cRT, in 35% of iRT, and 26% 
of nRT and Cmax was below 50 mg/L in 52% of cRT, 8% of iRT, and 
27% of nRT. When controlling for plasma creatinine and albumin 
concentration, dose interval, administered dose/kg and BMI, cRT 
remained significantly associated with an increased risk of a Cmin level 
below 10 mg/L (OR = 3.1; P= 0.001) compared with nRT. There was 
an inverse and independent association between administered dose/
kg and Cmax below 50 mg/L (OR = 2.0; P = 0.003). Trough levels 
> 20 mg/L were mainly seen in nRT patients with renal impairment 
with only 2 cases of mild CK elevation.
Conclusion: Daptomycin exposure is highly variable depending on 
renal function and renal replacement therapy used. Patients undergo-
ing cRT had the highest proportion of low daptomycin exposure with 
the highest risk for possible under dosing.
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